Skip to main content

NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Clinical Trials Using Docetaxel

Review the clinical trials studying docetaxel on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 110

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Status: Active
Location: 1041 locations
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People with Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment with Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 416 locations
Docetaxel and Hormone Treatment Compared to Hormone Treatment Alone in People with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response, TRIPLE-SWITCH Trial
Status: Active
Location: 377 locations
Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer
Status: Active
Location: 332 locations
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Status: Active
Location: 211 locations
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Status: Active
Location: 163 locations
Testing the use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy with Docetaxel plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Status: Active
Location: 146 locations
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Status: Active
Location: 29 locations
Donor NK Cell Therapy in Combination with Gemcitabine and Docetaxel for the Treatment of Relapsed or Refractory Sarcomas, The TINKS Trial
Status: Active
Location: 22 locations
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Status: Active
Location: 20 locations
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Status: Active
Location: 21 locations
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: 18 locations
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Status: Active
Location: 19 locations
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Status: Active
Location: 18 locations
A Study of ASP3082 in Adults With Advanced Solid Tumors
Status: Active
Location: 18 locations
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Status: Active
Location: 17 locations
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Status: Active
Location: 15 locations
Dose-Reduced Docetaxel with Cyclophosphamide for the Treatment of Vulnerable Older Women with Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Status: Active
Location: 15 locations
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Status: Active
Location: 11 locations
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Status: Active
Location: 12 locations
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Status: Active
Location: 11 locations
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
Status: Active
Location: 9 locations
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Status: Active
Location: 10 locations
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Status: Active
Location: 9 locations
Circulating Tumor DNA Monitoring for Treatment Response Prediction and Treatment Reduction after Surgery in Patients with Stage IB, II, and IIIB Non-small Cell Lung Cancer, DNA-PREDICT Trial
Status: Active
Location: 9 locations